Cardiol Therapeutics, Inc. (CRDL)
2.29
+0.07
(+3.15%)
USD |
NASDAQ |
Sep 09, 16:00
2.32
+0.03
(+1.31%)
After-Hours: 17:10
Cardiol Therapeutics Enterprise Value : 238.96M for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | 238.96M |
| September 04, 2026 | 236.64M |
| September 03, 2026 | 232.00M |
| September 02, 2026 | 233.16M |
| September 01, 2026 | 230.84M |
| August 31, 2026 | 210.56M |
| August 28, 2026 | 206.51M |
| August 27, 2026 | 220.41M |
| August 26, 2026 | 229.69M |
| August 25, 2026 | 213.46M |
| August 24, 2026 | 197.24M |
| August 21, 2026 | 197.24M |
| August 20, 2026 | 200.14M |
| August 19, 2026 | 208.83M |
| August 18, 2026 | 201.29M |
| August 17, 2026 | 190.28M |
| August 14, 2026 | 190.28M |
| August 13, 2026 | 179.86M |
| August 12, 2026 | 157.84M |
| August 11, 2026 | 155.52M |
| August 10, 2026 | 152.04M |
| August 07, 2026 | 146.25M |
| August 06, 2026 | 139.30M |
| August 05, 2026 | 136.98M |
| August 04, 2026 | 139.30M |
| Date | Value |
|---|---|
| August 03, 2026 | 133.50M |
| July 31, 2026 | 128.87M |
| July 30, 2026 | 121.91M |
| July 29, 2026 | 114.96M |
| July 28, 2026 | 120.75M |
| July 27, 2026 | 115.54M |
| July 24, 2026 | 118.44M |
| July 23, 2026 | 124.23M |
| July 22, 2026 | 130.02M |
| July 21, 2026 | 125.39M |
| July 20, 2026 | 124.81M |
| July 17, 2026 | 121.91M |
| July 16, 2026 | 124.23M |
| July 15, 2026 | 110.32M |
| July 14, 2026 | 114.96M |
| July 13, 2026 | 104.53M |
| July 10, 2026 | 98.74M |
| July 09, 2026 | 96.65M |
| July 08, 2026 | 97.58M |
| July 07, 2026 | 98.74M |
| July 06, 2026 | 105.69M |
| July 02, 2026 | 103.37M |
| July 01, 2026 | 103.37M |
| June 30, 2026 | 104.53M |
| June 29, 2026 | 95.48M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| InMed Pharmaceuticals, Inc. | -0.3727M |
| NervGen Pharma Corp. | 171.87M |
| Milestone Pharmaceuticals, Inc. | 111.28M |
| Clearmind Medicine, Inc. | -12.46M |
| Lexaria Bioscience Corp. | 11.56M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -4.393M |
| Total Expenses (Quarterly) | 4.393M |
| EPS Diluted (Quarterly) | -0.0382 |
| Earnings Yield | -10.81% |
| Normalized Earnings Yield | -10.93 |